Faes Farma S.A. Logo

Faes Farma S.A.

FAE | MC

Overview

Corporate Details

ISIN(s):
ES0134950F36
LEI:
959800FXZQY7U3P1G969
Country:
Spain
Address:
AVENIDA AUTONOMIA, 10-, 48940 Leioa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Faes Farma S.A. is an international pharmaceutical company, founded in 1933, that engages in the research, development, manufacturing, and marketing of pharmaceutical products and animal nutrition solutions. The company operates through two primary divisions: Pharma & Healthcare and FARM Faes. The Pharma division provides treatments for common global health issues, including allergic, gastrointestinal, and immune-related conditions, featuring proprietary molecules such as the leading antihistamine Bilastine and Calcifediol for Vitamin D deficiency. The FARM Faes division develops and markets specialized nutritional solutions and supplements for sustainable animal production. With a strong focus on R&D and a direct presence in Europe, Latin America, Africa, and the Middle East, Faes Farma serves both human and animal health markets globally.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Faes Farma S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-16 00:00
Post-Annual General Meeting Information
Acuerdo Junta Extraordinaria de Accionistas
Spanish 115.9 KB
2025-06-25 00:00
Post-Annual General Meeting Information
Aspectos relevantes de la Junta de Accionistas 2025
Spanish 159.0 KB
2025-06-25 00:00
Investor Presentation
Presentación Junta de Accionistas 2025
Spanish 4.2 MB
2025-06-11 00:00
Pre-Annual General Meeting Information
Junta General Extraordinaria de Accionistas
Spanish 167.3 KB
2025-05-19 15:51
Pre-Annual General Meeting Information
Convocatoria de la Junta General de Accionistas de 2025
Spanish 180.2 KB
2025-05-19 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General de Accionistas de 2025
Spanish 180.2 KB
2025-05-06 08:25
Investor Presentation
Informe de negocio del primer trimestre de 2025
Spanish 1.7 MB
2025-04-29 16:08
Report Publication Announcement
Faes Farma anuncia la celebración de un webcast para presentar los resultados d…
Spanish 65.2 KB
2025-04-22 11:39
Investor Presentation
Presentación Capital Markets Day 2025
Spanish 4.7 MB
2025-04-22 09:56
Investor Presentation
La Sociedad comunica que hoy celebrará su Capital Markets Day para presentar el…
Spanish 55.7 KB
2025-03-25 18:09
M&A Activity
Faes Farma S.A. ha suscrito un contrato para la adquisición de Laboratorios Edo…
Spanish 67.7 KB
2025-02-28 07:55
Investor Presentation
Informe de negocio y resultados 2024
Spanish 1.2 MB
2025-02-28 07:52
Major Shareholding Notification
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
Spanish 426.0 KB
2025-02-28 07:51
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
Spanish 213.3 KB
2025-02-28 00:00
Annual / Quarterly Financial Statement
Spanish 12.1 MB

Automate Your Workflow. Get a real-time feed of all Faes Farma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Faes Farma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
H. Lundbeck A Logo
Global pharmaceutical company creating innovative treatments for brain diseases.
Denmark HLUN
Hong Kong N/A
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL
Idorsia Ltd Logo
Develops novel medicines for CNS, cardiovascular, immunological, and orphan diseases.
Switzerland IDIA
Immuno-Biological Laboratories Co., Ltd. Logo Japan 4570
Indivior PLC Logo
A global pharmaceutical firm developing treatments for addiction and mental illness.
United Kingdom INDV
Infant Bacterial Therapeutics Logo
Developing microbiome therapies for premature infants to prevent life-threatening intestinal disease.
Sweden IBT
Intercure Ltd. Logo
Producer of pharma-grade, GMP-certified medical cannabis products for patients outside North America.
Israel INCR
Intervacc AB Logo
Develops recombinant protein vaccines for animal health, led by its vaccine for equine strangles.
Sweden IVACC
Ipsen Logo
Develops transformative medicines for Oncology, Rare Diseases, and Neuroscience.
France IPN